THE two “dissident” directors at the heart of the recent boardroom dispute at Irish pharmaceutical firm Elan are to leave their posts — resolving the row.

IRISH pharmaceutical company Elan has said that it remains on course to achieve record revenue growth and EBITDA of more than $150 million (€116m) in 2010, despite posting a $215m (€167) net loss for the first six months of the year.